NanoString sinks after IPO
This article was originally published in Clinica
Executive Summary
NanoString Technologies saw its stock close at $8.06 per share on 26 June – 19.4% below its already discounted IPO price. NanoString, a molecular diagnostics specialist, planned to raise $86.3 million and set a $13-15 price range for 5.4 million shares (www.clinica.co.uk, 4 June 2013) before ultimately launching its IPO at $10 for gross proceeds of $54 million. The Seattle, Washington-based company's breast cancer test Prosigna is available in the EU and Israel, but is not approved in the US.
You may also be interested in...
Xaira Launches With $1bn-Plus And End-To-End AI Strategy
ARCH and Foresite incubated the company and recruited Genentech R&D veteran Marc Tessier-Lavigne to keep data generation, machine learning research and drug development under one roof.
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Sanofi Clinches Key Phase III Immunology Win With Rilzabrutinib
Sanofi’s BTK inhibitor – one of two from its 2021 Principia buy – passed a Phase III test in immune thrombocytopenia as the company focuses on Dupixent-like blockbusters going forward.